TERNS PHARMACEUTICALS INC. - COMMON STOCK

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

03 May 2023 16:05:01 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates

27 Mar 2023 16:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology

27 Mar 2023 08:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Provides Program Updates and Announces Participation at Upcoming March Investor Conferences

02 Mar 2023 16:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in Guggenheim Healthcare Talks 2023 Oncology Conference

02 Feb 2023 16:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at B. Riley Securities’ 3rd Annual Oncology Conference

12 Jan 2023 16:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Highlight 2023 Priorities and Clinical Milestones at the 41st Annual J.P. Morgan Healthcare Conference

05 Jan 2023 16:05:00 By Nasdaq GlobeNewswire

Terns Announces Closing of Public Offering of Shares of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

23 Dec 2022 16:05:00 By Nasdaq GlobeNewswire

Terns Announces Pricing of $75 Million Public Offering

20 Dec 2022 19:39:56 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

20 Dec 2022 08:05:00 By Nasdaq GlobeNewswire

Terns Announces Proposed Public Offering

19 Dec 2022 16:31:04 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at the 2022 JMP Securities Hematology and Oncology Summit

01 Dec 2022 16:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights

09 Nov 2022 16:05:01 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Highlights Results from Phase 1 Clinical Trial of TERN-501 at AASLD The Liver Meeting® 2022

04 Nov 2022 08:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present Positive Clinical Data in NASH at AASLD The Liver Meeting® 2022

26 Oct 2022 16:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at the H. C. Wainwright 6th Annual NASH Investor Conference

11 Oct 2022 16:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

07 Sep 2022 16:05:00 By Nasdaq GlobeNewswire

Terns Announces $65 Million Oversubscribed Offering

12 Aug 2022 08:00:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights

08 Aug 2022 16:05:02 By Nasdaq GlobeNewswire

Terns Announces Appointment of Radhika Tripuraneni, M.D., M.P.H. to Board of Directors

27 Jul 2022 16:05:00 By Nasdaq GlobeNewswire